Core Viewpoint - 科前生物 is a leading company in the veterinary biological products sector in China, focusing on animal vaccine research and development, with strong financial performance and growth potential in the coming years [1][2][5]. Financial Performance - In Q3 2025, 科前生物 reported revenue of 738 million yuan, ranking 8th in the industry, with the top competitor 中牧股份 generating 4.442 billion yuan [2]. - The net profit for the same period was 337 million yuan, placing the company 2nd in the industry, with 瑞普生物 leading at 391 million yuan [2]. - The company's main business, veterinary biological products, accounted for 94.64% of total revenue, while other segments contributed 4.46% [2]. Profitability and Debt Management - As of Q3 2025, 科前生物's asset-liability ratio was 12.21%, lower than the previous year's 12.94% and significantly below the industry average of 28.36%, indicating strong debt repayment capability [3]. - The gross profit margin was 66.96%, an increase from 64.01% year-on-year and higher than the industry average of 40.13%, reflecting robust profitability [3]. Management and Shareholder Information - The chairman, 陈慕琳, received a salary of 1.6389 million yuan in 2024, up from 1.591 million yuan in 2023, an increase of 47,900 yuan [4]. - As of September 30, 2025, the number of A-share shareholders increased by 2.41% to 9,713, while the average number of shares held per shareholder decreased by 2.36% [5]. Growth Prospects - The company has been actively engaged in new product development, obtaining four new veterinary drug registration certificates in the first half of 2025, including a new inactivated vaccine for pigs [5][6]. - Forecasts suggest that 科前生物's revenue will grow to 1.038 billion yuan in 2025, 1.200 billion yuan in 2026, and 1.395 billion yuan in 2027, with net profits projected at 428 million yuan, 519 million yuan, and 610 million yuan respectively [5][6].

Market Overview - The animal health sector experienced a decline of 2.79% on October 30, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Individual Stock Performance - Jinhe Biology (002688) closed at 6.25, down 7.13% with a trading volume of 578,000 shares and a transaction value of 367 million yuan [1] - Keqian Biology (688526) closed at 16.15, down 6.76% with a trading volume of 139,800 shares and a transaction value of 228 million yuan [1] - Maofeng Holdings (002141) closed at 3.92, down 5.08% with a trading volume of 461,300 shares and a transaction value of 18.3 million yuan [1] - Other notable declines include Dayu Biology (920970) down 2.69%, and Pulaike (603566) down 2.68% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 84.7 million yuan from institutional investors, while retail investors experienced a net outflow of 16.5 million yuan [1] - Speculative funds recorded a net inflow of 101 million yuan [1] Detailed Capital Flow for Selected Stocks - Keqian Biology (688526) had a net inflow of 39.6 million yuan from institutional investors, while retail investors saw a net outflow of 60.9 million yuan [2] - Huisheng Biology (300871) experienced a net inflow of 18.3 million yuan from institutional investors, with a net outflow of 21.2 million yuan from retail investors [2] - Other stocks like Pulaike (603566) and Maofeng Holdings (002141) also reported significant net outflows from institutional investors [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown continuous improvement in profitability, with a 10.87% increase in revenue and a 29.62% increase in net profit for the first three quarters of 2025 [7] - The company is focusing on new product launches, with significant R&D investments and a rich pipeline of new veterinary drugs [7] - The company is expected to achieve revenue of 1.038 billion yuan in 2025, with a projected net profit of 428 million yuan, reflecting a growth trajectory [7] Financial Performance Summary - Revenue for 2023 is projected at 1,064 million yuan, with a revenue growth rate of 6.3% [6] - The net profit for 2023 is estimated at 396 million yuan, with a net profit growth rate of -3.3% [6] - The company’s gross margin for the first three quarters of 2025 is 66.96%, an increase of 2.95 percentage points year-on-year [7] - The net profit margin for the same period is 45.62%, up by 6.55 percentage points year-on-year [7] R&D and Product Development - The company invested 71.87 million yuan in R&D in the first three quarters of 2025, representing 9.74% of its revenue [7] - The company has received multiple new veterinary drug registrations, including vaccines for various diseases [7] - Ongoing product development includes vaccines currently in the registration phase, indicating a strong future growth potential [7] Future Projections - Revenue projections for 2025-2027 are 1.038 billion yuan, 1.200 billion yuan, and 1.395 billion yuan respectively [7] - Net profit projections for the same period are 428 million yuan, 519 million yuan, and 610 million yuan respectively [7] - The price-to-earnings ratio (PE) is expected to decrease from 18.9 in 2025 to 13.2 by 2027, indicating potential for value appreciation [7]

Core Insights - The company reported a total revenue of 738 million yuan for Q3 2025, ranking 7th among disclosed peers [1] - The net profit attributable to shareholders was 338 million yuan, with a net cash inflow from operating activities of 316 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 12.21%, an increase of 0.84 percentage points from the previous quarter [3] - The gross profit margin is 66.96%, a decrease of 0.32 percentage points compared to the previous quarter, with a return on equity (ROE) of 8.10% [4] - The diluted earnings per share (EPS) is 0.72 yuan [5] - The total asset turnover ratio is 0.16 times, ranking 10th among disclosed peers, while the inventory turnover ratio is 1.87 times, ranking 9th, which is a decrease of 0.01 times year-on-year, reflecting a 0.51% decline compared to the same period last year [5] Shareholder Structure - The number of shareholders is 9,713, with the top ten shareholders holding a total of 348 million shares, accounting for 74.56% of the total share capital [5] - The top shareholders include Wuhan Huazhong Agricultural University Asset Management Co., Ltd. (16.7%), Chen Huan Chun (15.2%), and Jin Mei Lin (7.87%) [5]

Core Viewpoint - 科前生物 reported a decline in operating revenue for Q3 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - Operating revenue for Q3 2025 was 251 million yuan, a year-on-year decrease of 5.44% [1] - Net profit attributable to shareholders was 118 million yuan, reflecting a year-on-year increase of 9.17% [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 84.62 million yuan, a year-on-year decrease of 7.06% [1]

Group 1 - The core viewpoint of the article is that 科前生物 (KQ Bio) reported a decline in operating revenue for Q3 2025, while net profit showed an increase year-on-year [1] Group 2 - The operating revenue for Q3 2025 was 251 million yuan, representing a year-on-year decrease of 5.44% [1] - The net profit attributable to shareholders of the listed company was 118 million yuan, which is a year-on-year increase of 9.17% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 84.62 million yuan, reflecting a year-on-year decrease of 7.06% [1]

证券代码：688526 证券简称：科前生物 公告编号：2025-054 武汉科前生物股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 14 日 14 点 00 分 召开地点：湖北武汉东湖新技术开发区高新二路 419 号科前生物二楼会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-051 武汉科前生物股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 10 月 29 日以通讯的形式召开第四届监事会第十五次会议（下称"本次会 议"）。本次会议通知于 2025 年 10 月 19 日以邮件、电话的方式向 各位监事发出，本次会议由监事会主席吴斌先生主持，本次会议应参 与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、召开程 序均符合《公司法》、《证券法》等法律、法规和规范性文件以及《公 司章程》的规定。 监事会认为：公司 2025 年第三季度报告的编制和审议程序符合 相关法律法规、公司章程及公司管理制度的有关规定。报告的内容与 格式符合有关规定，公允地反映了公司 2025 年第三季度的财务状况 和经营成果等事项。报告披露的信息真实、准确、完整，不存在任何 虚假记载、误导性陈述或重大遗漏。 具体内容详见同日 ...

Company Performance - In Q3 2025, the company reported revenue of approximately 738 million yuan, representing a year-on-year increase of 10.87% [1] - The net profit attributable to shareholders was approximately 338 million yuan, showing a year-on-year increase of 29.62% [1] - Basic earnings per share reached 0.72 yuan, which is a year-on-year increase of 28.57% [1] Market Context - The company's market capitalization is currently 8.1 billion yuan [2] - The A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's new "slow bull" pattern [2]

武汉科前生物股份有限公司 总经理工作细则 二○二五年十月 第一章 总则 第一条 为规范武汉科前生物股份有限公司（以下简称"公司"）总经理的工作行为， 保障总经理依法履行职权，根据《中华人民共和国公司法》（以下简称《公司法》）等有 关法律、法规、规范性文件以及《武汉科前生物股份有限公司章程》（以下简称"公司 章程"）的规定，制定本细则。 第二条 总经理履行职权除应遵守本细则的规定外，还应符合相关法律、法规、规 范性文件和公司章程的规定。 第二章 经理人员的职权范围 第一节 经理人员的职责 第三条 公司经理人员应忠实履行职责，维护公司和全体股东的最大利益，并负有 下述忠实义务： (一) 不得侵占公司的财产、不得挪用公司资金； (二) 不得将公司资产或者资金以其个人名义或者其他个人名义开立账户存储； (三) 不得利用职权贿赂或者收受其他非法收入； (四) 未向董事会或者股东会报告，并按照公司章程的规定经董事会或者股东会决议 通过，不得直接或者间接与本公司订立合同或者进行交易； (五) 不得利用职务便利，为自己或者他人谋取属于公司的商业机会，但向董事会或 者股东会报告并经股东会决议通过，或者公司根据法律、行政法规或者 ...